

Metoclopramide and selective oral decontamination for avoiding pneumonia after stroke

Submission date 29/09/2016	Recruitment status Stopped	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 10/10/2016	Overall study status Stopped	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 05/04/2019	Condition category Circulatory System	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

A stroke is a serious, life-threatening medical condition that occurs when the blood supply to part of the brain is cut off. People who have had a stroke often lose the ability to swallow. This can cause food and saliva to get into their airways. If this happens, there is an increased risk of developing pneumonia, which is a life threatening and highly weakening condition. Even treatment with antibiotics may not prevent the weakening effects of pneumonia from delaying recovery, or worsening the condition. In such stroke patients, food is provided through a tube directly into the stomach to prevent food entering the airways. Stroke patients are still at risk however, as moving and turning can lead to vomiting. Vomit can easily be inhaled into airways, especially when lying down. Additionally saliva, containing bacteria that can cause pneumonia when inhaled, can build up as the patient cannot swallow. The aim of this study is to test two ways of preventing pneumonia in stroke patients who are being fed through a tube. The first method is to prevent patients vomiting using a drug called metoclopramide. This drug is well known to prevent vomiting and the NHS use it widely in other patients. The second method is to use an antibiotic paste in the patient's mouth to reduce the bacteria in their saliva. Both methods have been shown in smaller studies to decrease the number of patients who develop pneumonia and the number of resulting deaths.

Who can participate?

Adult patients who have had a stroke within the last 9 hours, who have swallowing problems and are receiving tube feeding

What does the study involve?

All participants receive a 'drug' and a 'mouth paste' but neither the participant nor the clinicians know whether the participant is getting a 'real' drug or paste or a placebo (dummy). Participants are randomly allocated into four groups:

1. Metoclopramide and placebo paste
2. Metoclopramide and antibiotic paste
3. Placebo metoclopramide and antibiotic paste
4. Placebo metoclopramide and placebo paste

Participants are monitored daily for signs and symptoms of pneumonia, as well as any treatment side effects for 14 days. On day 30, participants are assessed to see how they are recovering from their stroke. On day 90, participants and/or their families receive a phone call from the study team to see how they are doing, how they are eating (is the tube still in), where they are living (home, care home, hospital) and assess their quality of life. All collected data is analysed by the team to see if either treatment can prevent pneumonia and reduce the number of deaths in these patients, and to see if there are cost savings from preventing pneumonia by reducing length of stay, accelerating rehabilitation and preventing use of systemic antibiotics. Antibiotic resistance is a growing problem and reduction in antibiotic use is an important national target for the NHS.

What are the possible benefits and risks of participating?

The participant may be given metoclopramide for a longer period than for up to 21 days. Metoclopramide is normally given for 5 days to prevent vomiting although it can be given for longer. The main side effect of this is tardive dyskinesia (involuntary movements of the face and jaw), although this tends to develop well after the 21 days this study is proposing it be used for. The patient will be observed on a daily basis and if these symptoms start to occur, the use of the drug will be stopped. The mouth paste is currently not licenced for use in the UK, although it is widely used in the Netherlands. As with all antibiotic treatment it has the potential to cause antibiotic resistance and patients will be monitored for this.

Where is the study run from?

Fifty different hospitals from across the UK, led by Keele University (UK)

When is the study starting and how long is it expected to run for?

January 2017 to September 2019

Who is funding the study?

Health Technology Assessment Programme (UK)

Who is the main contact?

Prof. Christine Roffe

Contact information

Type(s)

Scientific

Contact name

Prof Christine Roffe

ORCID ID

<https://orcid.org/0000-0002-5259-6649>

Contact details

Institute for Applied Clinical Sciences (IACS)

Keele University

Guy Hilton Research Centre

Thornburrow Drive

Hartshill

Stoke-on-Trent

United Kingdom
ST4 7QB

Additional identifiers

Clinical Trials Information System (CTIS)
2016-003406-14

Protocol serial number
HTA 14/49/154

Study information

Scientific Title

The Metoclopramide and selective oral decontamination for Avoiding Pneumonia after Stroke (MAPS-2) Trial: a 2x2 double-blind, randomised controlled trial of metoclopramide and selective oral decontamination for the prevention of pneumonia in patients with dysphagia after an acute stroke

Acronym
MAPS-2

Study objectives

Early interventions aimed at the prevention of pneumonia reduce mortality and improve recovery after stroke.

More details can be found at: <http://www.nets.nihr.ac.uk/projects/hta/1449154>

Ethics approval required
Old ethics approval format

Ethics approval(s)
North West-Greater Manchester Central Research Ethics Committee, 04/04/2017, ref: 17/NW/0058

Study design
2x2 factorial double-blind randomised controlled trial

Primary study design
Interventional

Study type(s)
Treatment

Health condition(s) or problem(s) studied
Stroke

Interventions
This study will test two ways of preventing pneumonia in stroke patients who are being fed through a tube. The first method will be to prevent patients from vomiting using a drug called

metoclopramide. This drug is well known to prevent vomiting and the NHS use it widely in other patients. The second method is to use an antibiotic paste in the patient's mouth to reduce the bacteria in their saliva. Both methods have been shown, in smaller separate studies, to decrease the number of patients who develop pneumonia and the number of resulting deaths. All patients recruited will receive a 'drug' and a 'mouth paste' but neither the patient nor the clinicians will know whether the patient is getting a 'real' drug or paste or a placebo. Patients are randomised into four groups:

1. Metoclopramide and placebo paste
2. Metoclopramide and antibiotic paste
3. Placebo metoclopramide and antibiotic paste
4. Placebo metoclopramide and placebo paste

Patients will then be monitored daily for signs and symptoms of pneumonia, as well as any treatment side effects for 14 days (as of 04/09/2017 this has been updated to 21 days). On day 30, patients will be assessed to see how they are recovering from their stroke (neurologically). On day 90, patients and/or their families will receive a phone call from the MAPS-2 team to see how they are doing physically, how they are eating (is the tube still in), where they are living (home, care home, hospital) and what quality of life is like for them. All collected data will be analysed by the team to see if either treatment can prevent pneumonia and reduce the number of deaths in these patients. Health economics will be analysed to see if cost savings result from preventing pneumonia by reducing length of stay, accelerating rehabilitation and preventing use of systemic antibiotics.

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Metoclopramide, SOD Paste is made up of colistin, tobramycin and amphotericin b

Primary outcome(s)

Mortality up to the end of the study (90 days). The patients' vital status will be assessed during months 26-32, giving a maximum follow-up of 24 months for participants recruited in month 1 and 3 months for participants recruited at the end of the study. This will be done by phone call to the GP, and, where necessary, the participant or the contacts they provide. Missing data will be ascertained with the team who recruited the patient, and via linkage with Hospital Episode Statistics, Office of National Statistics, and Sentinel Stroke National Audit datasets.

Key secondary outcome(s)

1. Pneumonia within 14 days. This is taken from data collected on the daily log. The study team will look at the clinical diagnosis and indication for antibiotics and CDC and modified MANN criteria.
2. Number of days of antibiotic treatment for pneumonia within the first 30 days
3. Neurological recovery measured using the National Institutes of Health Stroke Scale (NIHSS) at 30 days
4. Disability measured using the modified Rankin Scale (mRS) at 90 days
5. Quality of life measured using the EuroQol five dimensions questionnaire (EQ-5D) at 90 days

Completion date

01/10/2020

Reason abandoned (if study stopped)

Lack of funding/sponsorship

Eligibility

Key inclusion criteria

1. Adult patients with a clinical diagnosis of acute stroke
2. Within 9 hours of stroke onset
3. Moderate to severe neurological impairment with and NIHSS score of 10 or above
4. Unable to take a normal oral diet or fluids because too drowsy to be assessed formally or failed bedside assessment of swallowing

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

All

Key exclusion criteria

1. Evidence of vomiting since stroke onset
2. Pre-existing swallowing problem
3. Known oesophageal pathology that might interfere with placement of a nasogastric tube
4. Probable or definite pneumonia
5. Contraindications to metoclopramide, epilepsy, gastrointestinal obstruction, perforation, or haemorrhage, gastrointestinal surgery within the last week, Parkinson's disease, treatment with levodopa or dopaminergic agonists, pheochromocytoma or neuroleptic malignant syndrome or tardive dyskinesia or methaemoglobinaemia or NADH cytochrome
6. Patients with severe liver disease or kidney disease
7. Known allergy to colistin
8. Pregnant or breastfeeding
9. Other co-morbid conditions with a life expectancy of less than 3 months at the discretion of the clinical treating team
10. Inability to gain consent from the patient or a legal representative or refusal of consent

Date of first enrolment

01/12/2017

Date of final enrolment

31/03/2019

Locations

Countries of recruitment

United Kingdom

England

Study participating centre**Stroke Research Group**

Institute of Applied Clinical Sciences

Keele University

Guy Hilton Research Centre

Thornburrow Drive

Hartshill

Stoke-on-Trent

United Kingdom

ST4 7QB

Sponsor information**Organisation**

University Hospitals North Midlands (UHNM) NHS Trust

ROR

<https://ror.org/03g47g866>

Funder(s)**Funder type**

Government

Funder Name

Health Technology Assessment Programme

Alternative Name(s)

NIHR Health Technology Assessment Programme, Health Technology Assessment (HTA), HTA

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location

Results and Publications

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study will be available upon request from Professor Christine Roffe.

IPD sharing plan summary

Available on request

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
HRA research summary			28/06/2023	No	No
Participant information sheet	version V2.1	10/03/2017	04/09/2017	No	Yes
Study website	Study website	11/11/2025	11/11/2025	No	Yes